Agilis Biotherapeutics has entered into an exclusive worldwide license agreement with the University of South Florida for the treatment of using gene therapy technology developed by Edwin Weeber, PhD, Director of the Neurobiology of Learning and Memory and Chief Scientific Officer at the USF Health Byrd Alzheimer's Research Institute at the University of South Florida, and one of the world’s foremost AS investigators.
Dr. Weeber and colleagues have developed an innovative gene therapy approach for the treatment of AS and recently published evidence of therapeutic efficacy in the gold standard mouse model.
|Searching for more deal information? Current Partnering offers the following options:
Agilis’ collaboration with Dr. Weeber and USF will target the genetic malfunctions of AS using gene therapy to deliver a corrective UBE3a gene to rescue neurological deficits in patients suffering from this rare disease.
Under the terms of the agreement, Agilis will be granted worldwide, exclusive rights to AS gene therapy candidates and related intellectual property.